z-logo
Premium
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients
Author(s) -
KosiTrebotic Lana,
Thomas Anita,
Harreiter Jürgen,
Chmelik Marek,
Trattnig Siegfried,
KautzkyWiller Alexandra
Publication year - 2017
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12817
Subject(s) - medicine , metformin , diabetes mellitus , endocrinology , type 2 diabetes , cirrhosis , basal (medicine) , gastroenterology , waist , fatty liver , body mass index , disease
Background Increased hepatic fat and cardiac fat are common in patients with type 2 diabetes mellitus (T2 DM ) and are associated with a greater risk of liver fibrosis and cardiovascular ( CV ) events. Sex‐specific differences of dipeptidyl peptidase‐four ( DPP ‐4) inhibitor effects on hepatic ( HCL ) and myocardial fat content ( MYCL ) have not yet been evaluated. Method Forty‐one T2 DM patients (20 male, 21 female) received a gliptin add‐on therapy if HbA1c goals were not reached under metformin monotherapy. They underwent cardiac and liver magnetic resonance tomography and spectroscopy before and 6 months after therapy initiation. Plasma samples were analysed for the growth differentiation factor 15 ( GDF ‐15), a novel marker for cardiovascular risk. Results Thirty‐eight patients on gliptin therapy completed the study. We observed a positive correlation between MYCL and HCL before therapy ( R  = 0·41, P  = 0·05). After 6 months of therapy, we noticed a significant weight reduction in women only ( P  = 0·02) whereas waist circumference decreased similarly in both sexes. HbA1c sunk significantly in both sexes ( P  = 0·002). HCL decreased significantly ( P  = 0·0004), with women featuring higher basal HCL ( P  < 0·05). MYCL decreased in women only ( P  = 0·01) and GDF ‐15 comparably in both sexes ( P  < 0·05). Conclusions 6 months of DPP ‐4‐therapy led to a significant overall decrease in HCL and body weight such as a reduction of MYCL only in women. This preliminary data set could implicate that gliptin may be a feasible therapy option in fatty liver patients with diabetes potentially including positive effects on cardiovascular function particularly in women.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here